NIDUS is a collaborative, multidisciplinary network dedicated to the acceleration of scientific discovery in delirium research, through focused collaboration and creation of sustainable infrastructure to enhance innovative and high-quality research.

NIDUS was created in response to a call from the National Institutes on Aging to support a collaborative network to advance scientific research on the causes, mechanisms, outcomes, diagnosis, prevention, and treatment of delirium in older adults.

NIDUS II Pilot Grant Information Session (09/09/21)

Learn more about the NIDUS Focus Areas

Delirium Research Hub

Improving research collaboration

Measurement & Harmonization

Developing measurement resources

Pilot Awards & Innovation

Encouraging novel research in delirium

Mentoring & Career Development

Developing the future of delirium research

Dissemination & Communication

Communicating news from the delirium field

NIDUS Registration

Sign up for FREE NIDUS membership with access to delirium resources

NIDUS mailing list

Sign up for our email list to receive our newsletters and occasional program announcements

Follow us on Twitter!

Recent Posts

Patricia A. Tabloski, Ph.D., GNP-BC, FGSA, FAAN is an associate professor at the Connell School of Nursing

Patricia A. Tabloski, PhD, GNP-BC, FGSA, FAAN

Patricia A. Tabloski, Ph.D., GNP-BC, FGSA, FAAN is an associate professor at the Connell School of Nursing. Dr. Tabloski’s work focuses on the epidemiology and treatment of various threats to quality of life and function in older adults. This work has involved elucidating risk factors for poor outcomes, the development and testing of non-pharmacologic interventions […]

C. Adrian Austin, MD, MSCR

Selective Serotinin Reuptake Inhibitor (SSRI) Use and Delirium Occurrence in the ICU

Contributed by C. Adrian Austin, MD, MSCR, Divisions of Geriatric Medicine and Pulmonary Diseases and Critical Care Medicine, University of North Carolina School of Medicine, Chapel Hill, NC Anxiety, depression and ICU delirium may be linked.1 Approximately 10% of the U.S. population takes an antidepressant, most commonly a selective serotonin reuptake inhibitor (SSRI).2 It remains […]

Delirium Research Hub by the Numbers